NCT00227461

Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Kessler Foundation · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.

Detailed description

In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design.

Conditions

• Aphasia
• Stroke

Interventions

Type	Name	Description
DRUG	Wait first, then levetiracetam	Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.
DRUG	Levetiracetam first, then wait	subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design

Timeline

• Start date: 2005-09-01
• Primary completion: 2021-12-01
• Completion: 2021-12-01
• First posted: 2005-09-28
• Last updated: 2021-02-17

Locations

1 site across 1 country: United States